Truist analyst Michael Lewis downgraded Sabra Health Care (SBRA) to Hold from Buy with a price target of $17, down from $18. The firm cites relative valuation for the downgrade, after the stock was up 31% last year vs. 9% for REITs overall. While Sabra Health Care REIT is still a little cheaper than some of its peers, Truist projects slightly below average FFO and FAD growth over the next three- and five-year periods, and thinks there may be better opportunities elsewhere, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue